Searchable abstracts of presentations at key conferences in endocrinology

ea0090p455 | Reproductive and Developmental Endocrinology | ECE2023

Decreased Quality of Life in Previous Users of Anabolic Androgenic Steroids Years After Cessation

Bulut Yeliz , Brandt-Jacobsen Niels , Kistorp Caroline , Rasmussen Jon J.

Background and Aim: Use of anabolic androgenic steroids (AAS) has moved from elite sports to the broader population. Studies suggest that AAS cessation is often associated with immediate various AAS withdrawal and hypogonadal symptoms. Quality of life using a standardized questionnaire has never been assessed in AAS users. The Short-Form 36 (SF-36) questionnaire is a highly validated and used instrument for assessment of quality of life. The questionnaire consists of a total e...

ea0016p365 | Growth factors | ECE2008

Association between serum levels of insulin-like growth factor-I and development of congestive heart failure: a prospective study in a normal population

Andreassen Mikkel , Raymond Ilan , Kistorp Caroline , Hildebrandt Per , Faber Jens

Background: The growth hormone system (growth hormone, GH and insulin-like-growth-factor I, IGF-I) might be implicated in congestive heart failure (CHF). In experimental models IGF-I increases cardiac contractility and reduces apoptosis of myocytes exposed to ischemic injury. In clinical studies GH-therapy has been used in CHF. One previous population based investigation showed that low levels of IGF-I was associated with an increased incidence of CHF. The result of this inves...

ea0014p371 | (1) | ECE2007

Increased risk of cardiovascular events in subclinical hyperthyroidism

Schultz Marianne , Kistorp Caroline , Raymond Ilan , Faber Jens

Objective: Untreated overt hyperthyroidism is known to predispose the patient to cardiovascular diseases, while predisposition in subclinical hyperthyroidism has been debated. The1 cut-off point of TSH for initiating treatment in subclinical hyperthyroidism is still undefined.Method: A community-based prospective study including non-hospitalised participants, aged 51 to 91 years, living in Copenhagen, Denmark were examined between September 1998 and Janu...

ea0090oc9.6 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Previous use of anabolic androgenic steroids is associated with persistent impaired myocardial microcirulation

Bulut Yeliz , J. Rasmussen Jon , Brandt-Jacobsen Niels , Lassen Martin Lyngby , Hasbak Philip , Kistorp Caroline

Background and Aim: Ongoing anabolic androgenic steroids (AAS) use has been linked with left ventricle dysfunction, while information on the effects years after discontinuation is limited. Furthermore, the underlying mechanism behind the impaired cardiac function is unknown. Early signs of cardiomyopathy, such as microvascular dysfunction with global or regional reduced myocardial perfusion can be measured noninvasively by cardiac positron emission tomography (PET) with Rubidi...

ea0090p184 | Reproductive and Developmental Endocrinology | ECE2023

Human muscle fibers in previous users of anabolic steroids display persistent increased myonuclei number years after cessation

Rasmussen Jon , Nielsen Jakob , Frandsen Mikkel , Bulut Yeliz , Brandt-Jacobsen Niels , Aagaard Per , Kistorp Caroline

Background and Objective: Information on the long-term effects of anabolic androgenic steroids (AAS) use on the myocellular properties of human skeletal muscle is scarce, despite being the primary target of AAS. Animal studies suggest persistence of upregulated myonuclei numbers following AAS discontinuation. Few human studies have investigated the effects of AAS on human skeletal muscle cell morphology and exclusively focused on current AAS users. No data exist elucidating th...

ea0090p448 | Reproductive and Developmental Endocrinology | ECE2023

Persistent effects of anabolic, androgenic steroids on muscle mass and strengths years after cessation?

Hoeg Brandt-Jacobsen Niels , Fredberg Jeppe , Rasmussen Jon , Bulut Yeliz , Kistorp Caroline

Objective: The use of anabolic, androgenic steroids (AAS) to increase muscle mass and strength has become widespread among younger men engaged in recreational strength training. Although, repercussions exist for elite athletes with a ban of two to four years, the long-term effects on muscle mass following cessation are currently unknown. The present study aims to investigate previous users’ ability to retain lean mass and strength after long-term AAS cessation.<p clas...

ea0049ep63 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment with modified-release hydrocortisone for 6 months: A clinical audit in 15 patients with adrenal insufficiency

Steffensen Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Kistorp Caroline , Jorgensen Jens Otto L

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

ea0035p651 | Female reproduction | ECE2014

Copeptin in polycystic ovary syndrome

Frossing Signe , Aziz Mubeena , Skouby Sven O , Kistorp Caroline , Faber Jens

Background: Polycystic ovary syndrome (PCOS) is according to the Rotterdam criteria defined as minimum two of: oligomenoré, hyperandrogenism and polycystic ovary. These criteria do not take into account PCOS’ association with the metabolic syndrome (MES) and ischaemic heart disease (IHD). Recently we grouped PCOS- patients into four phenotypes depending on normal/high BMI and insulin resistance (IR). We demonstrated that PCOS-patients with high BMI and increased IR h...

ea0029p319 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Body composition and association to NT-proBNP and myostatin levels in heart failure patients

Christensen H. , Kistorp C. , Schou M. , Zerahn B. , Keller N. , Faber J.

Objectivs: Plasma NT-proBNP is inversely associated with BMI in patients with heart failure (HF). A possible mechanism may be the lipolytic effect of natriuretic peptides on abdominal fat.Myostatin is previously described as a negative regulator of skeletal muscle mass in cachexia.We assessed the hypothesis that body composition is related to plasma NT-proBNP and that myostatin levels are associated with loss of fat free mass (FFM)...

ea0026p568 | Cardiovascular endocrinology and lipid metabolism | ECE2011

Plasma levels of the neurohormones A and B-type natriuretic peptides increases after weight loss in severe obesity

Kistorp C , Christensen R , Goetze J P , Bliddal H , Faber J

Introduction: The neurohormones A and B-type natriuretic peptides are markedly increased in patients with heart disease, and are well established as useful diagnostic biomarkers. Obesity is a known risk factor for cardiovascular disease. Cross sectional data suggest however that plasma levels are reduced among obese. Therefore, the aim of the present study was to investigate the impact of weight loss and corresponding changes in body composition on plasma levels of A and B-typ...